Drugs in the Pipeline
Mirvetuximab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer
Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.